The FDA has approved Bristol Myers Squibb’s Cobenfy, an oral medication for schizophrenia in adults. Analysts predict significant potential for the drug, particularly in treating Alzheimer’s related psychosis, with projected peak sales exceeding $6 billion. However, despite its first-mover advantage, Cobenfy faces competition from AbbVie’s emraclidine, while potential side effects are also noted.